DNIB Unwind Company Profile (NASDAQ:BIND)

About DNIB Unwind (NASDAQ:BIND)

DNIB Unwind logoDNIB Unwind, Inc., formerly BIND Therapeutics, Inc. is a shell company. The Company was engaged in developing targeted therapeutics, primarily for the treatment of cancer. As of August 1, 2016, the Company sold all of its assets. The Company's subsidiaries include BIND (RUS) LLC and DNIB Subsidiary Corporation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIND
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.52
  • 200 Day Moving Avg: $1.17
  • 52 Week Range: $0.35 - $5.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.80
  • P/E Growth: 0.00
Misc:
  • Average Volume: 1.20 million shs.
  • Beta: 2.79
 

Frequently Asked Questions for DNIB Unwind (NASDAQ:BIND)

What is DNIB Unwind's stock symbol?

DNIB Unwind trades on the NASDAQ under the ticker symbol "BIND."

How were DNIB Unwind's earnings last quarter?

DNIB Unwind Inc (NASDAQ:BIND) announced its quarterly earnings results on Monday, May, 9th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.06. The company had revenue of $1.87 million for the quarter, compared to the consensus estimate of $3.83 million. View DNIB Unwind's Earnings History.

Who are some of DNIB Unwind's key competitors?

How do I buy DNIB Unwind stock?

Shares of DNIB Unwind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of DNIB Unwind stock cost?

One share of DNIB Unwind stock can currently be purchased for approximately $0.87.

Analyst Ratings

Consensus Ratings for DNIB Unwind (NASDAQ:BIND) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for DNIB Unwind (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/6/2016Stifel NicolausReiterated RatingHoldN/AView Rating Details
4/7/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
4/7/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
4/7/2016Oppenheimer Holdings Inc.DowngradeMarket PerformN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$9.00 -> $6.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for DNIB Unwind (NASDAQ:BIND)
Earnings by Quarter for DNIB Unwind (NASDAQ:BIND)
Earnings History by Quarter for DNIB Unwind (NASDAQ:BIND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2016Q116($0.55)($0.61)$3.83 million$1.87 millionViewListenView Earnings Details
3/15/2016Q415($0.49)($0.37)$3.35 million$6.40 millionViewListenView Earnings Details
11/2/2015Q315($0.52)($0.49)$3.14 million$2.10 millionViewN/AView Earnings Details
8/6/2015Q215($0.51)($0.51)$3.88 million$2.50 millionViewListenView Earnings Details
5/7/2015Q115($0.51)($0.44)$2.67 million$4.40 millionViewListenView Earnings Details
3/11/2015Q414($0.40)($0.51)$6.00 million$3.00 millionViewListenView Earnings Details
11/6/2014($0.31)($0.44)ViewN/AView Earnings Details
8/7/2014Q214($0.60)($0.51)$2.20 million$2.46 millionViewN/AView Earnings Details
5/9/2014($0.49)($0.51)ViewN/AView Earnings Details
3/25/2014($0.41)($0.50)ViewN/AView Earnings Details
11/5/2013Q313($0.67)($2.70)$1.66 million$4.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DNIB Unwind (NASDAQ:BIND)
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for DNIB Unwind (NASDAQ:BIND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for DNIB Unwind (NASDAQ:BIND)
Insider Trades by Quarter for DNIB Unwind (NASDAQ:BIND)
Institutional Ownership by Quarter for DNIB Unwind (NASDAQ:BIND)
Insider Trades by Quarter for DNIB Unwind (NASDAQ:BIND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2013Noubar AfeyanDirectorBuy20,000$15.00$300,000.00View SEC Filing  
9/25/2013Polaris Venture Management Co.Major ShareholderBuy26,000$15.00$390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for DNIB Unwind (NASDAQ:BIND)
Latest Headlines for DNIB Unwind (NASDAQ:BIND)
Source:
DateHeadline
finance.yahoo.com logoBIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets
finance.yahoo.com - January 3 at 4:22 PM
finance.yahoo.com logoBIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets
finance.yahoo.com - January 3 at 4:22 PM
seekingalpha.com logoMedical Marijuana Offers Opportunities For The Daring Investor - Seeking Alpha
seekingalpha.com - October 27 at 4:08 PM
seekingalpha.com logoMedical Marijuana Offers Opportunities For The Daring Investor - Seeking Alpha
seekingalpha.com - October 27 at 4:08 PM
fool.com logoBetter Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. - Motley Fool
www.fool.com - October 18 at 8:40 AM
streetinsider.com logoForm S-8 POS DNIB UNWIND, INC. - StreetInsider.com - StreetInsider.com
www.streetinsider.com - October 15 at 8:40 AM
streetinsider.com logoForm 8-K DNIB UNWIND, INC. For: Oct 11 - StreetInsider.com
www.streetinsider.com - October 11 at 3:53 PM
globenewswire.com logoNanotechnology Drug Delivery Market to reach US$ 11.9 Billion in 2023; Transparency Market Research - GlobeNewswire (press release)
globenewswire.com - September 29 at 3:22 PM
finance.yahoo.com logoNanotechnology Drug Delivery Market to reach US$ 11.9 Billion in 2023; Transparency Market Research
finance.yahoo.com - September 27 at 3:52 PM
nasdaq.com logoDelisting of Securities of BIND Therapeutics, Inc., InterCloud Systems, Inc., Echo Therapeutics, Inc., 1347 Capital ... - Nasdaq
www.nasdaq.com - September 25 at 3:35 PM
globenewswire.com logoDelisting of Securities of BIND Therapeutics, Inc., InterCloud Systems, Inc., Echo Therapeutics, Inc., 1347 Capital ... - GlobeNewswire (press release)
globenewswire.com - September 24 at 3:45 PM
finance.yahoo.com logoHercules’ Leading Originations Platform Continues to Finance Some of the Most Promising Innovative and …
finance.yahoo.com - September 15 at 12:44 PM
finance.yahoo.com logoSiamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium - Yahoo Finance
finance.yahoo.com - September 13 at 8:43 AM
globenewswire.com logoBeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317 - GlobeNewswire (press release)
globenewswire.com - September 12 at 8:38 AM
prnewswire.com logoXencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute ... - PR Newswire (press release)
www.prnewswire.com - September 12 at 8:38 AM
businesswire.com logoProclara Biosciences Announces $47 Million in New Investment to ... - Business Wire (press release)
www.businesswire.com - September 7 at 3:51 PM

Social

Chart

DNIB Unwind (BIND) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff